Herein, we designed a novel compound against CD26-positive cancers, which is constituted with YS110 and triptolide derivative TR-1 (Figure 1), an inhibitor for one of the general transcription factors for Pol II, TFIIH, and designated Y-TR1 [14]. The gene discussed is DPP4; the disease is cancer.